The firm is prioritizing development of its anti-DKK1 antibody sirexatamab following promising Phase II results in microsatellite-stable colorectal cancer.

The firm must deprioritize a mitochondrial disease program in order to fast-track PBGENE-DMD to a Phase I study.

NEW YORK – Patients with refractory solid tumors that express NKG2DL began receiving Leucid Bio's autologous CAR T-cell therapy LEU011 in a Phase I trial, the firm said earlier this week. The trial, ...

Based on promising preclinical data, researchers hope to begin clinically testing PLK1-targeted treatments in young people with fibrolamellar carcinoma.

Having established improved cancer detection, the interval cancer rate will reveal whether AI catches certain early cancers missed by standard screening.